Physician profile

Uma Chatterjee

Obstetrics & Gynecology · Newark, DE

NPI 1689760290

$619.85

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$124.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $258.48 2019-2024 Veozah
Abbvie INC. $92.36 2019-2020
Therapeuticsmd, INC. $85.35 2019-2020
Lupin INC. $52.53 2019-2020
Amag Pharmaceuticals, INC. $48.15 2019-2020
Evofem Biosciences, INC. $20.53 2021
Aspira Women'S Health INC $18.04 2020
Exeltis, USA INC. $17.50 2022
Novo Nordisk INC $14.63 2019
Bayer Healthcare Pharmaceuticals INC. $12.28 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Uma Chatterjee

$619.85

in general payments reported 2019-2025

Years
2019-2024
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/212692/uma-chatterjee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.